COMBO内镜口咽通气道在消化内镜中的有效性与安全性:多中心随机对照试验研究方案
本研究为多中心、随机、开放标签、两臂平行组、优效性临床试验,计划纳入1200例接受丙泊酚镇静消化内镜的患者,比较COMBO内镜口咽通气道与传统鼻导管对缺氧发生率的影响。主要结局为缺氧发生率(75%≤SpO2<90%且持续时间<60秒)。
要点
- COMBO内镜口咽通气道是一种新型氧合与气道管理方法。
- 研究计划纳入1200例丙泊酚镇静消化内镜患者,随机分为传统鼻导管组与COMBO内镜口咽通气道组。
- 主要结局为缺氧发生率(75%≤SpO2<90%且持续时间<60秒)。
核心结论
- 本研究旨在探讨COMBO内镜口咽通气道能否降低丙泊酚镇静消化内镜患者的缺氧发生率。
- 作者认为若研究成功,该方案可能在预防丙泊酚镇静消化内镜期间低氧血症的气道管理方面代表显著进步。
研究设计与样本
- 多中心、随机、开放标签、两臂平行组、优效性临床试验,设有活性对照。
- 计划纳入1200例接受丙泊酚镇静消化内镜的患者。
- 纳入标准为择期上消化道内镜手术、年龄≥18岁且≤60岁、美国麻醉医师协会分级I-II级、预计检查时间≤45分钟。
- 参与者将被随机分配到传统鼻导管组(第1组)或COMBO内镜口咽通气道组(第2组)。
主要发现
- 主要目标为缺氧发生率(75%≤SpO2<90%且持续时间<60秒)。
- 次要目标为亚临床缺氧(90%≤SpO2<95%)和严重缺氧(SpO2<75%,或75%≤SpO2<90%且持续时间≥60秒)的发生率及其他不良事件。
关键数值与推荐
- 缺氧定义:75%≤SpO2<90%且持续时间<60秒。
- 亚临床缺氧定义:90%≤SpO2<95%。
- 严重缺氧定义:SpO2<75%,或75%≤SpO2<90%且持续时间≥60秒。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypoxia is one of the most common adverse events of sedated gastrointestinal (GI) endoscopy. It can cause coronary ischemia and permanent nervous system damage, potentially leading to death if not promptly addressed. This study aims to examine the efficacy and safety of the COMBO (capnography monitoring bite block oxygenation) endoscopy oropharyngeal airway in patients undergoing sedated GI endoscopy. METHODS: A multicenter randomized, open-label, two-arm parallel-group superiority clinical trial with an active comparator will be conducted to evaluate the impact of the COMBO endoscopy oropharyngeal airway on the incidence of hypoxia. This study will include patients (n = 1200) undergoing GI endoscopy under propofol sedation. Written informed consent will be obtained from them. The participants (patients undergoing elective upper gastrointestinal endoscopic surgery, ≥ 18 years old and ≤ 60 years old, American Society of Anesthesiologists Grade I-II, expected inspection time ≤ 45 min) will be randomly assigned to a conventional nasal cannula (Arm 1)or the COMBO endoscopy oropharyngeal airway group (Arm 2). The intervention group will be administered the COMBO endoscopy oropharyngeal airway correspondingly. The primary objective is the incidence of hypoxia (75% ≤ SpO2 < 90% for < 60 s). The secondary objective is the incidence rate of subclinical hypoxia (90% ≤ SpO2 < 95%) and severe hypoxia (SpO2 < 75% or 75% ≤ SpO2 < 90% for ≥ 60 s), and other adverse events. DISCUSSION: The COMBO endoscopy oropharyngeal airway is a novel method for oxygenation and airway management. This study is aimed at investigating whether the COMBO endoscopy oropharyngeal airway can reduce the incidence of hypoxia in patients during gastrointestinal endoscopy under sedation with propofol. If successful, our proposal could play a pivotal role that represents a significant advancement in airway management in preventing hypoxemia during GI endoscopy under propofol sedation. TRIAL REGISTRATION: ClinicalTrials.gov NCT06081647, registered on October 15, 2023.
引用
- Zhang Y, Shi M, Qu Y, et al. Efficacy and safety of the COMBO endoscopy oropharyngeal airway in gastrointestinal endoscopy: a study protocol for a multicenter randomized controlled trial. Trials. 2025. PMID: 41390738. doi:10.1186/s13063-025-09351-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。